Leading Cancer Researcher: They’re Ignoring My Research, Cancer Patients Must Know This!

Cancer originates as a mitochondrial metabolic disease rather than a purely genetic one, where damage to the mitochondria forces cells to rely on ancient fermentation pathways fueled by glucose and glutamine. This metabolic shift drives the dysregulated cell growth that characterizes cancer. Professor Thomas Seyfried advocates for the Glucose Ketone Index (GKI) as a critical biomarker for monitoring mitochondrial health, suggesting that therapeutic ketosis and fasting can starve tumor cells of their primary fuels. By shifting the body into a state of nutritional ketosis, patients can protect healthy cells and enhance the efficacy of conventional treatments like chemotherapy. This metabolic approach offers a strategy to manage cancer by targeting the bioenergetic vulnerabilities of tumor cells, potentially improving survival outcomes and quality of life for patients facing terminal diagnoses.